Publications

5491 Results

Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

Authors
B Darst;J Shen;R Madduri;A Rodriguez;Y Xiao;X Sheng;E Saunders;T Dadaev;M Brook;T Hoffmann;K Muir;P Wan;L LeMarchand;L Wilkens;Y Wang;J Schleutker;R MacInnis;D Albanes;C Tangen;Z Kote-Jarai;S Watya;J Gaziano;A Justice;D Conti;C Haiman
Journal / Conference
American Journal of Human Genetics Jul 6;110(7):1200-1206
Year
2023
Research Committee(s)
Cancer Control and Prevention and Epidemiology
PMID
PMID37292833
PMC
PMC10246022
Study Number(s)
S0000, SWOG-9217

A Randomized Phase 2 Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) with HER2 Amplification: SWOG S1613

Authors
K Raghav;K Guthrie;S Kopetz;B Tan;C Denlinger;M Fakih;M Overman;N Dasari;L Corum;L Hicks;M Patel;B Esparaz;S Kazmi;N Alluri;S Colby;S Gholami;P Gold;EG Chiorean;H Hochster;PA Philip
Journal / Conference
ASCO GI Cancers Symposium (January 19-21, 2023, San Francisco, CA), poster
Year
2023
Research Committee(s)
Gastrointestinal
Study Number(s)
S1613

Phase II study of docetaxel and trametinib in patients with G12C and non-G12C KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT)

Authors
S Gadgeel;J Miao;J Riess;P Mack;G Gerstner;T Burns;A Taj;W Akerley;K Dragnev;N Laudi;J Moon;JE Gray;DR Gandara;KL Kelly
Journal / Conference
Clinical Cancer Research May 26;CCR-22-3947. doi: 10.1158/1078-0432.CCR-22-3947. Online ahead of print
Year
2023
Research Committee(s)
Lung
PMID
PMID37233987
PMC
PMC10526968
Study Number(s)
S1507

Novel Approaches for Dynamic Visualization of Adverse Event Data in Oncology Clinical Trials: A Case Study Using Immunotherapy Trial S1400-I (SWOG)

Authors
S Lee;W Fan;A Wang;R Vaidya;M Redman;S Gettinger;L Bazhenova;R Herbst;D Hershman;J Unger
Journal / Conference
JCO Clinical Cancer Informatics Apr;7:e2200165
Year
2023
Research Committee(s)
Lung
PMID
PMID37084329
PMC
PMC10281446
Study Number(s)
S1400I

Subclonal TP53 mutation are frequent and predict resistance to radio-immunotherapy in follicular lymphoma

Authors
R Burack;H Li;D Adlowitz;J Spence;L Rimsza;M Shadman;C Spier;M Kaminski;J Leonard;M LeBlanc;S Smith;J Friedberg
Journal / Conference
Blood Advances Sep 12;7(17):5082-5090
Year
2023
Research Committee(s)
Lymphoma
PMID
PMID37379264
PMC
PMC10471938
Study Number(s)
S0016

The effect of ctDNA Tumor Fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP

Authors
P Mack;M Redman;D Kozono;S Callis;H Tukachinsky;K Tolba;J Neal;S Waqar;K Dragnev;C Aggarwal;F Hirsch;J Patel;R Herbst;A Chiang;K Reckamp;K Kelly;H Borghaei;J Gray;D Gandara
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 9035); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), poster session
Year
2023
Research Committee(s)
Lung
Study Number(s)
LUNGMAP

ECOG-ACRIN LUNG-MAP S1900E Substudy (NCT04625647): A Phase II Study of Sotorasib in Participants (Pts) With Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous (Non-sq) Non-Small Cell Lung Cancer (NSCLC)

Authors
S Padda;M Redman;D Gerber;T Stinchcombe;S Waqar;T Leal;K Minichiello;K Reckamp;R Herbst;H Borghaei;J Brahmer;J Gray;K Kelly;S Ramalingam;J Neal
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr TPS9143); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), tip, poster session
Year
2023
Research Committee(s)
Lung
Study Number(s)
S1900E

SWOG S1929: Phase II Randomized Study of Maintenance Atezolizumab (A) Versus Atezolizumab + Talazoparib (AT) in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Authors
N Abdel Karim;J Miao;K Reckamp;C Gay;L Byers;Y Zhao;M Redman;D Carrizosa;W Wang;W Petty;K Mehta;B Faller;E Agamah;S Kasbari;Rajini Malisetti;A Kumar;J Schallenkamp;K Alluri;J Gray;K Kelly
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 8504); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Lung
Study Number(s)
S1929

Chemotherapy Induced Peripheral Neuropathy (CIPN) due to Paclitaxel versus Docetaxel in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)

Authors
M Trivedi;J Unger;D Hershman;A Darke;D Hertz;T Brannagan;S Smith;B Schneider;W Irvin;A Hathaway;A Vander Woude;V Gudena;NL Henry;M Fisch
Journal / Conference
J Clin Oncol 41, 2023 (suppl 16; abstr 12003); ASCO Annual Meeting (June 2-6, 2023, Chicago, IL), oral
Year
2023
Research Committee(s)
Symptom Control and Quality of Life
Study Number(s)
S1714

Image analysis-based tumor infiltrating lymphocyte measurement predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer (SWOG S0800)

Authors
K Fanucci;K Blenman;Y Bai;V Pelekanou;Z Nahleh;S Shafi;S Burela;W Barlow;P Sharma;A Thompson;A Godwin;D Rimm;G Hortobagyi;L Pusztai
Journal / Conference
NPJ Breast Cancer May 13;9(1):38
Year
2023
Research Committee(s)
Breast
PMID
PMID37179362
PMC
PMC10182981
Study Number(s)
S0800